About

About TFF

We are focused on developing innovative drug products based on our patented Thin Film Freezing, or TFF, technology platform.

Although intended for the lungs, many drugs are not given via the airway because drug properties make it too difficult to formulate for direct to lung delivery.

Administered systemically, these drugs often produce unwanted and potentially life-threatening side effects. To get around this, companies have tried to use microcapsules, carriers, and other agents to try to dose drugs direct to the lungs, but these other delivery agents often produce their own problems.

Using its proprietary technology, TFF can generate dry powder inhaler versions of many drugs using nothing but the drug itself and approved lung-friendly ingredients. This means that many drugs of all types – small molecules, biologics, even combinations – can be dosed direct to the lungs with fewer side effects.

Management

Glenn Mattes

President, Chief Executive Officer and Director

Read Bio

Brian Windsor, Ph.D.

Director & CSO

Read Bio

Kirk Coleman

Chief Financial Officer

Read Bio

Board of Directors

Glenn Mattes

President, Chief Executive Officer and Director

Read Bio

Brian Windsor, Ph.D.

Director & CSO

Read Bio

Aaron Fletcher, Ph.D.

Chairman of the Board

Read Bio

Robert S. Mills

Executive Chairman of the Board

Read Bio

Stephen Rocamboli

Board Member

Read Bio

Harlan Weisman, M.D.

Director

Read Bio

Randy Thurman

Board Member

Read Bio

Collaboration Opportunities

We continue to work with the inventors of the TFF platform through a series of Sponsored Research Agreements, or SRAs, with UT. Pursuant to those agreements, the research scientists, together with their labs and collaborators, provide expertise and initial development work, including:

  • the preliminary development and in vitro evaluation of our drug candidates;
  • the determination of the key characteristics influencing performance of our product candidates;
  • the determination of the formulation and manufacturing parameters that influence the key characteristics of our product candidates;
  • supply of bulk dry powders for initial good laboratory practice, or GLP, and non-GLP toxicity studies;
  • supportive stability for future GLP and GMP studies; and
  • the evaluation of the in vivo performance of our product candidates in various animal models.

Pathway to Market

Because our dry powder drug candidates will represent a new formulation of an existing drug, we will need to obtain FDA approval of the TFF prepared drug candidate before we can begin commercialization. However, because we begin our formulation with a drug that has previously received FDA approval in another form, we believe that in most cases we should qualify for the FDA’s 505(b)(2) regulatory pathway, which potentially will take less time and investment than the standard FDA approval process.

Top